Supported by an educational grant from Amicus Therapeutics
TITLE - Advances in Fabry Disease: An Overview of Clinical Considerations, Diagnosis, & Treatment for the Healthcare Professional
TARGET AUDIENCE - Target audiences for this program are Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Nephrology Pharmacists, Nephrology Nurses and Nurses
LEARNING OBJECTIVES - After completing the program, Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Nephrology Pharmacists, Nephrology Nurses and Nurses, along with other healthcare practitioner participants will be able to:
- Describe the epidemiology and pathophysiology of Fabry Disease
- List the phenotypes of Fabry Disease
- Recognize the various clinical presentation and complications associated with Fabry Disease
- Describe Fabry Disease diagnosis and challenges associated with early identification
- Identify differential diagnoses
- Describe treatment options for patients with Fabry Disease and treatment-related adverse events
- Review clinical data for investigational agents in development for treatment of Fabry Disease
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/ services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by the Specialty Pharma Education Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Pharmacist continuing education credit
Specialty Pharma Education Center (SPEC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hour (0.1CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Knowledge Based Activity
Course release date 10/1/2018
Course expires 10/1/2021
Nursing continuing education credit
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Provider # 5-115. This program is approved for 1 hour of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Course release date: 10/1/2018
Course expiration date: 10/1/2020
|Activity Number||Credit Amount||Accreditation Period|
|0535-0000-18-019-H01-P||0.1 CEUs||October 01, 2018 - October 01, 2021|
|0535-0000-18-019-H01-N||1 hour of CNE||October 01, 2018 - October 01, 2020|